Table 2.
Comparisons of clinical characteristics and laboratory parameters with different grades of severity of hypertriglyceridemic acute pancreatitis
|
Characteristic
|
All (n = 219)
|
MAP group (n = 29)
|
MSAP group (n = 114)
|
SAP group (n = 76)
|
P
value
|
| Sex, n (%) | 0.111 | ||||
| Male | 140 (63.9) | 23 (79.3) | 67 (58.8) | 50 (65.8) | |
| Female | 79 (36.1) | 6 (20.7) | 47 (41.2) | 26 (34.2) | |
| Age, yr | 38.92 ± 10.02 | 38.66 ± 9.73 | 38.96 ± 10.12 | 38.96 ± 10.12 | 0.941 |
| BMI (kg/m2) | 26.13 ± 3.30 | 26.20 ± 1.56 | 25.58 ± 3.54 | 28.51 ± 2.97 | 0.097 |
| Complications, n (%) | |||||
| Diabetes mellitus | 109 (49.8) | 14 (48.3) | 58 (50.9) | 37 (48.7) | 0.982 |
| Fatty liver disease | 205 (93.6) | 25 (86.2) | 106 (93.0) | 74 (97.4) | 0.112 |
| Lipid-lowering treatment, n (%) | < 0.001 | ||||
| Intravenous insulin | 84 (38.4) | 14 (48.3) | 69 (60.5) | 1 (1.3) | |
| HP | 32 (14.6) | 1 (3.4) | 26 (22.8) | 5 (6.6) | |
| CRRT/HP + CRRT | 60 (27.4) | 0 (0.0) | 1 (0.9) | 59 (77.6) | |
| Only anti-lipemic | 43 (19.6) | 14 (48.3) | 18 (15.8) | 11 (14.5) | |
| Improved Marshall score | 1.00 (0.00, 3.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 1.00) | 3.00 (3.00, 4.75) | < 0.001 |
| MCTSI score | 5.11 ± 1.70 | 2.14 ± 0.92 | 5.14 ± 1.06 | 6.18 ± 1.35 | < 0.001 |
| Baseline TG, mg/dL | 2713.82 ± 2458.65 | 1895.15 ± 1685.17 | 2480.80 ± 2040.458 | 3386.29 ± 3081.51 | 0.035 |
| Baseline AMY (nUNL) | 2.92 (1.43, 6.41) | 2.81 (1.47, 5.21) | 2.22 (0.98, 5.08) | 5.28 (2.21, 8.66) | < 0.001 |
| CRP, mg/L | 196.36 ± 121.97 | 143.17 ± 97.51 | 178.65 ± 103.25 | 247.12 ± 143.73 | < 0.001 |
| Albumin, g/L | 32.66 ± 5.99 | 36.48 ± 4.96 | 34.46 ± 5.16 | 28.49 ± 5.16 | < 0.001 |
| TBIL, mmol/L | 16.60 (10.80, 22.90) | 18.91 (13.02, 23.68) | 15.35 (10.69, 22.46) | 16.57 (10.60, 24.92) | 0.511 |
| ALT, U/L | 20.00 (13.60, 30.70) | 21.30 (14.90, 35.75) | 20.25 (13.00, 31.93) | 19.75 (14.03, 27.30) | 0.648 |
| AST, U/L | 25.00 (17.50, 39.50) | 21.30 (17.00, 28.05) | 20.00 (16.08, 30.63) | 36.55 (25.00, 56.80) | < 0.001 |
| Total cholesterol, mmol/L | 8.58 ± 4.56 | 7.47 ± 2.96 | 8.82 ± 4.53 | 8.64 ± 5.06 | 0.522 |
| HDL-C, mmol/L | 0.82 (0.61, 1.10) | 0.88 (0.75, 1.17) | 0.86 (0.66, 1.16) | 0.69 (0.52, 0.99) | 0.241 |
| LDL-C, mmol/L | 2.92 ± 1.55 | 3.77 ± 1.41 | 2.91 ± 1.58 | 2.62 ± 1.46 | 0.003 |
| Glucose, mmol/L | 10.50 ± 3.64 | 9.47 ± 3.70 | 10.34 ± 3.54 | 11.13 ± 3.69 | 0.100 |
| Urea nitrogen, mmol/L | 4.73 ± 3.31 | 4.56 ± 1.63 | 3.66 ± 1.76 | 6.40 ± 4.64 | < 0.001 |
| Creatinine, μmol/L | 83.03 ± 66.48 | 71.90 ± 18.03 | 65.46 ± 19.11 | 113.63 ± 103.46 | < 0.001 |
| Calcium, mmol/L | 1.93 ± 0.31 | 2.16 ± 0.18 | 2.00 ± 0.21 | 1.75 ± 0.37 | < 0.001 |
| WBC, × 109/L | 11.67 ± 4.10 | 11.22 ± 3.64 | 11.99 ± 4.06 | 11.37 ± 4.33 | 0.351 |
| PLT, × 109/L | 200.19 ± 69.19 | 194.69 ± 73.58 | 208.67 ± 65.17 | 189.57 ± 72.51 | 0.159 |
| Hb, g/L | 141.11 ± 24.52 | 143.69 ± 19.12 | 136.87 ± 22.76 | 146.49 ± 27.78 | 0.010 |
| STSH, mIU/L | 0.28 (0.16, 0.65) | 0.49 (0.28, 0.98) | 0.28 (0.14, 0.66) | 0.24 (0.16, 0.62) | 0.188 |
| FT3, pmol/L | 2.29 ± 1.00 | 2.90 ± 0.77 | 2.36 ± 0.86 | 2.89 ± 1.18 | 0.018 |
| FT4, pmol/L | 12.56 ± 3.70 | 12.83 ± 2.10 | 12.88 ± 3.95 | 12.11 ± 3.68 | 0.302 |
| Admission to ICU, n (%) | 98 (44.7) | 1 (3.4) | 27 (23.7) | 70 (92.1) | < 0.001 |
| Death, n (%) | 9 (4.1) | 0 (0.0) | 0 (0.0) | 9 (11.8) | < 0.001 |
MAP: Mild acute pancreatitis; MSAP: Moderately severe acute pancreatitis; SAP: Severe acute pancreatitis; BMI: Body mass index; HP: Hemoperfusion; CRRT: Continuous renal replacement therapy; MCTSI: Modified computed tomography severity index; TG: Triglyceride; AMY: Amylase; UNL: Upper limit of normal; CRP: C-reactive protein; TBIL: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate transaminase; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; WBC: White blood cell; PLT: Blood platelet; Hb: Hemoglobin; STSH: Sensitive thyrotropin; FT3: Free triiodothyronine; FT4: Free thyroxine; ICU: Intensive care unit.